Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-17

Study Completion Date

2022-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

* To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended dose (RD) of SAR408701 in Japanese patients with advanced malignant solid tumors.

Secondary Objectives:

* To characterize the overall safety profile of SAR408701 monotherapy.
* To characterize the pharmacokinetic (PK) profile of SAR408701 and its metabolites.
* To evaluate the pharmacodynamic (PDy) effect of SAR408701 on levels of circulating carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for main dose escalation part.
* To assess preliminary efficacy according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria and other indicators of antitumor activity.
* To assess the potential immunogenicity of SAR408701.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

NCT01392924

Neoplasm Malignant

COMPLETED PHASE1

Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors

NCT01391533

Malignant Solid Tumors

COMPLETED PHASE1

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

NCT03980821

Advanced Solid Malignancies

COMPLETED PHASE1

Study of NK012 in Patients With Refractory Solid Tumors

NCT00542958

Cancer

COMPLETED PHASE1

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

NCT00613652

Cancer Tumors Carcinoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study duration per participant will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an End-of-Treatment (EOT) visit around 30 days after the last administration of IMP, and at least one follow-up (FU) visit after the EOT visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasm Malignant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAR408701 Monotherapy

SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors

Group Type EXPERIMENTAL

SAR408701

Intervention Type DRUG

Pharmaceutical form: solution for infusion

Route of administration: intravenous

dexamethasone

Intervention Type DRUG

Pharmaceutical form: solution for eye drop

Route of administration: eye drop

naphazoline

Intervention Type DRUG

Pharmaceutical form: solution for eye drop

Route of administration: eye drop

diphenhydramine

Intervention Type DRUG

Pharmaceutical form: tablet

Route of administration: oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SAR408701

Pharmaceutical form: solution for infusion

Route of administration: intravenous

Intervention Type DRUG

dexamethasone

Pharmaceutical form: solution for eye drop

Route of administration: eye drop

Intervention Type DRUG

naphazoline

Pharmaceutical form: solution for eye drop

Route of administration: eye drop

Intervention Type DRUG

diphenhydramine

Pharmaceutical form: tablet

Route of administration: oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tusamitamab ravtansine Santeson ophthalmic solution Clearine Restamin Kowa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Locally advanced or metastatic solid malignant tumor disease for which, in the judgement of the investigator, no standard alternative therapy is available.
* Inclusion is likely to be expressing CEACAM5.
* At least 6 x 5 μm slides from formalin-fixed paraffin-embedded (FFPE) archival tissue should be available for retrospective central evaluation of CEACAM5 expression.
* Patient understands and has signed the Written Informed Consent form and is willing and able to comply with the requirements of the trial.

Exclusion Criteria

* Patient less than 20 years old.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2.
* Life expectancy \<12 weeks.
* Known or symptomatic brain metastasis (other than totally resected or previously irradiated and non-progressive/relapsing) or lepto-meningeal carcinomatosis.
* Female patients of childbearing potential and male patients with female partners of childbearing potential who do not agree to use accepted and effective method of contraception during the study treatment period and for 6 months following discontinuation of IMP.
* Significant concomitant illnesses, including all severe medical conditions which, in the opinion of the Investigator or Sponsor, would impair the patient's participation in the study or interpretation of the results.
* Prior therapy targeting CEACAM5.
* Prior maytansinoid treatments (maytansinoid derivative 1 \[DM1\] or maytansinoid derivative 4 \[DM4\] antibody drug conjugates).
* Previous history and or unresolved corneal disorders.
* Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by cytochrome P450 (CYP) and for which a dose reduction cannot be considered.
* Medical conditions requiring concomitant administration of strong CYP3A inhibitor, unless it can be discontinued at least 2 weeks before first administration of SAR408701.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes